FL-ELEVATE-PRIZE-FNDTN
10.3.2021 15:02:05 CET | Business Wire | Press release
The Elevate Prize Foundation is pleased to announce the launch of its second year of the Elevate Prize, which will commit $5 million in funding and services to 10 prize winners. The Foundation is searching for social impact leaders globally who are tackling the most pressing challenges of our time, with the most innovative and effective solutions.
Founders and CEOs of nonprofits and public charities worldwide are welcome to apply to win one of 10 annual Elevate Prizes. New this year is a simplified, two-phase application, making it significantly easier for nonprofit leaders to apply for the Prize. Phase 1, now open to all applicants, includes a shortened written application, while Phase 2 will include a more robust set of questions, released only to select applicants this summer.
The Elevate Prize Foundation, founded in 2019 by entrepreneur and philanthropist Joseph Deitch , is dedicated to giving unsung social entrepreneurs the necessary resources to scale their impact, and to ultimately help inspire and awaken the hero in all of us. The Foundation awarded its inaugural class of 10 winners in October 2020.
Each winner of this year’s Elevate Prize will receive:
- MONEY . A minimum of $300,000 (USD) shared between winners and their nonprofit organizations, so they can collectively drive change.
- AMPLIFICATION . Our strategic marketing and media expertise can take winners to the next level. Be a social impact influencer. Find fans. Build a platform. Think bigger. Do great things. Change the world.
- MENTORSHIP . Our network of partners, executives and decision-makers offer the kind of professional development and business guidance money can’t buy.
- CONNECTIONS . Each cohort is a radically diverse group of people leading innovative organizations. As a member of this cohort, winners will have the opportunity to learn from each other, create shared experiences, and build lasting relationships.
- SUPPORT . We take the time to thoroughly understand winners’ needs as an individual and organization, and then create a tailored program that will help each winner reach their goals and beyond.
“The Elevate Prize remains committed to finding a radically diverse group of innovative problem solvers, and investing unconventional and personalized resources that bring greater visibility to them as leaders and the vital work they do. We make good famous,” said Carolina García Jayaram, executive director, Elevate Prize Foundation.
The Foundation is proud to partner with MIT Solve on this year’s Elevate Prize. As an extension of its partnership, the Foundation will commit one of its 10 Prizes to MIT Solve’s first US Challenge on Antiracist Technology. The Elevate Prize for Antiracist Technology is open to nonprofit leaders who are helping to create an antiracist and equitable future in the U.S. This exemplar leader will take part in both the MIT Solver program and the Elevate Prize program and receive ongoing support from both organizations.
The application process for the Prize begins today at www.elevateprize.org/apply and applicants can submit up until the May 5 deadline. Following this deadline, select applicants will be invited to complete Phase 2 of the application. Winners will be announced in October 2021.
About the Elevate Prize Foundation
Founded in 2019 by businessman, philanthropist, and author Joseph Deitch, the Elevate Prize Foundation aims to elevate humanity on a global scale by funding, guiding, and scaling the platforms of social entrepreneurs. The Foundation’s signature program is its annual Elevate Prize – a search for innovators and activists that culminates with the selection of 10 leaders to receive funding and guidance to amplify their work. These changemakers are working to solve the world’s problems within healthcare, the environment, poverty, inequality, the arts, and more. Elevate Prize winners embark on a two-year program fueled by access to top scholars and industry leaders who guide and support them in scaling their impact. Together, Prize winners, advisors, partners, and collaborators across industries combine their impressive reach to create a single, powerful philanthropic amplification platform to awaken the hero in all of us. For more information, visit www.elevateprize.org and follow @ElevatePrize on Facebook, Instagram, LinkedIn, and Twitter.
About MIT Solve
Solve is an initiative of the Massachusetts Institute of Technology (MIT) with a mission to solve world challenges. Solve is a marketplace for social impact innovation. Through open innovation Challenges, Solve finds incredible tech-based social entrepreneurs all around the world. Solve then brings together MIT’s innovation ecosystem and a community of Members to fund and support these entrepreneurs to help them drive lasting, transformational impact. Join Solve on this journey at solve.mit.edu .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005111/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom